Kenneth Tokita, MD
Radiation Oncology · Irvine, CANPI 1447432653
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.
Across 110 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blue Earth Diagnostics$479
- Myovant Sciences Inc.$327
- Sumitomo Pharma America, Inc.$289
- Boston Scientific$221
- Bayer$197
- Pfizer$177
- plus $714 from 10 others
Across 20 payments — averaging $3661.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blue Earth Diagnostics$73K
What the payments were for
- Food & beverage$2,38099%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blue Earth Diagnostics | 19 | $479 |
| Myovant Sciences Inc. | 19 | $327 |
| Sumitomo Pharma America, Inc. | 14 | $289 |
| Boston Scientific | 7 | $221 |
| Bayer | 11 | $197 |
| Pfizer | 9 | $177 |
| Telix Pharmaceuticals | 7 | $159 |
| Progenics Pharmaceuticals, Inc. | 6 | $133 |
| Teleflex LLC | 3 | $112 |
| Dendreon Pharmaceuticals LLC | 4 | $104 |
| Tactile Systems Technology Inc | 5 | $72 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| Bioprotect Medical, Inc. | 1 | $28 |
| Palette Life Sciences, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Novartis | 1 | $18 |
How this compares
$2,404 in reported general payments places this provider in the 75th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 101 | $2,115 |
| Bicalutamide | 14 | $428 |
| Escitalopram Oxalate | 24 | $379 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Irvine
- Percy LeeIrvine$125K
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.